Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis

Abstract Background CD9 is implicated in cancer progression and metastasis by its role in suppressing cancer cell proliferation and survival. However, the prognostic and clinicopathological significance of CD9 expression is controversial. Therefore, the current meta-analysis was conducted to determine the prognostic and clinicopathological significance of CD9 expression in cancer patients. Methods Eligible studies were selected through database search of PubMed, Embase and Cochrane library up to April 5 2020. The necessary data were extracted from the included studies. Pooled hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were calculated to evaluate the prognostic and clinicopathological significance of CD9 expression in cancer patients. Results A total of 17 studies consisting of 3456 cancer patients were included in this meta-analysis. An increased CD9 expression was significantly associated with a more favorable overall survival (OS) (HR 0.47, 95% CI 0.31–0.73, p = 0.001) and disease-free survival (DFS) (HR 0.48, 95% CI 0.30–0.79, p = 0.003). In subgroup analysis of cancer type, an increased CD9 expression was associated with increased OS in breast cancer and digestive system cancer, and with increased DFS in head and neck cancer and leukemia/lymphoma. Additionally, an increased CD9 expression significantly correlated with lower overall stage (OR 0.45, 95% CI 0.29–0.72, p = 0.001). Conclusion An increased CD9 expression was associated with favorable survival in cancer patients suggesting that CD9 expression could be a valuable survival factor in cancer patients.

Download Full-text

The Significance of SIX1 as a Prognostic Biomarker for Survival Outcome in Various Cancer Patients: A Systematic Review and Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.622331 ◽

2021 ◽

Vol 11 ◽

Author(s):

Guang Zhu ◽

Ying Liu ◽

Lei Zhao ◽

Zhenhua Lin ◽

Yingshi Piao

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Cancer Patients ◽

Human Cancer ◽

Meta Analysis ◽

Disease Free Survival ◽

Cancer Type ◽

Free Survival ◽

Cancer Types ◽

Disease Free

Sine Oculis Homeobox Homolog 1 (SIX1) is reported to promote cancer initiation and progression in many preclinical models and is demonstrated in human cancer tissues. However, the correlation between SIX1 and cancer patients’ prognosis has not yet been systematically evaluated. Therefore, we performed a systematic review and meta-analysis in various human cancer types and extracted some data from TCGA datasets for further verification and perfection. We constructed 27 studies and estimated the association between SIX1 expression in various cancer patients’ overall survival and verified with TCGA datasets. Twenty-seven studies with 4899 patients are include in the analysis of overall, and disease-free survival, most of them were retrospective. The pooled hazard ratios (HRs) for overall and disease-free survival in high SIX1 expression patients were 1.54 (95% CI: 1.32-1.80, P<0.00001) and 1.83 (95% CI: 1.31-2.55, P=0.0004) respectively. On subgroup analysis classified in cancer type, high SIX1 expression was associated with poor overall survival in patients with hepatocellular carcinoma (HR 1.50; 95% CI: 1.17-1.93, P =0.001), breast cancer (HR 1.31; 95% CI: 1.10-1.55, P =0.002) and esophageal squamous cell carcinoma (HR 1.89; 95% CI: 1.42-2.52, P<0.0001). Next, we utilized TCGA online datasets, and the consistent results were verified in various cancer types. SIX1 expression indicated its potential to serve as a cancer biomarker and deliver prognostic information in various cancer patients. More works still need to improve the understandings of SIX1 expression and prognosis in different cancer types.

Download Full-text

The Prognostic Value of lncRNA SNHG3 in Cancer Patients: A meta-analysis

10.21203/rs.3.rs-91124/v1 ◽

2020 ◽

Author(s):

Jie Wang ◽

Pingyong Zhong ◽

Hao Hua

Keyword(s):

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Multiple Cancer ◽

Free Survival ◽

Node Metastasis ◽

Hazard Ratios ◽

Clinicopathological Significance

Abstract Background:Small nucleolar RNA host gene 3 (SNHG3) is a promising long non-coding RNA that may possess prognostic value for different types of tumors. The objective of this meta-analysis is to evaluate the prognostic value of lncRNA SNHG3 in cancer patients.Methods:A systematic literature search of the PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang electronic databases was carried out in this meta-anaysis. The synthetic hazard ratios (HRs) or odd ratios (ORs) with 95% confidence intervals (CIs) were obtained to determine the prognostic and clinicopathological significance of SNHG3 expression in tumors. Results:The final meta-anaysis included 17 studies that contained 2072 patients. The pooled results provided evidence that SNHG3 overexpression predicted reduced overall survival (OS) (HR=2.15, 95%CI: 1.76–2.63, P<0.00001), recurrence-free survival (RFS) ( HR=2.22, 95%CI: 1.04–4.76, P=0.04) and disease-free survival (DFS) (HR=2.04, 95%CI: 1.35–3.09, P=0.0007) for various cancers. Additionally, the SNHG3 overexpression was concerned with tumor node metastasis (TNM) stage (III/IV vs. I/II, OR=2.91, 95%CI: 1.60–5.29, P=0.0005), lymph node metastasis (LNM) (positive vs negative, OR=5.00,95%CI:2.82–8.87,P＜0.00001), distant metastasis (DM) (positive vs negative, OR=2.29, 95%CI: 1.52–3.47, P<0.0001) and tumor size (larger vs smaller, OR=1.80, 95%CI: 1.04–3.11, P=0.04).Conclusions:Our results indicated that SNHG3 overexpression was closely correlated with shorter OS in multiple cancer types, suggesting that SNHG3 might function as a promising predictor for clinical outcomes in cancer.

Download Full-text

Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

10.21203/rs.2.16573/v5 ◽

2020 ◽

Author(s):

Yuan Yuan ◽

Hai Zhong ◽

Liang Ye ◽

Qian Li ◽

rong su Fang ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Publication Bias ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Free Survival ◽

Lung Cancer Patients ◽

Platelet Counts

Abstract Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

Download Full-text

Prognostic value of platelet count in lung cancer: a systematic review and meta-analysis

10.21203/rs.2.16573/v1 ◽

2019 ◽

Author(s):

Yuan Yuan ◽

Hai Zhong ◽

Liang Ye ◽

Qian Li ◽

Rong Su Fang ◽

...

Keyword(s):

Lung Cancer ◽

Platelet Count ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Free Survival ◽

Lung Cancer Patients ◽

Pubmed Database

Abstract Background : The prognostic value of pretreatment elevated platelet count remains controversial in lung cancer patients. We performed the present meta-analysis to determine the precise role of it in these patients.Methods: We performed a multiple search strategy in PubMed database, EMBASE and Cochrane Library to identify eligible studies. Disease-free survival (DFS) /Progress-free survival (PFS)/Time to progress(TTP) and Overall survival (OS) were used as outcomes with hazard ratio (HR) and its 95% confidence intervals (CIs). Heterogeneity among studies and publication bias were also evaluated.Results : A total of 39 studies including 16696 lung cancer patients were eligible in the analysis. Overall, the pooled analysis showed that pretreatment elevated platelet count was associated with poorer OS (HR= 1.47, 95%CI: 1.31-1.66, P<0.001) and poorer DFS/PFS/TTP ((HR=1.63, 95%CI: 1.28-2.09, P<0.001) in patients with lung cancer compared with normal platelet count. In subgroup analyses, pretreatment elevated platelet count was also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias.Conclusions : This meta-analysis revealed that pretreatment elevated platelet count was an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large scale prospective studies and a validation study are warranted.

Download Full-text

Partial Versus Total Omentectomy in Patients with Gastric Cancer: A Systemic Review and Meta-Analysis

Cancers ◽

10.3390/cancers13194971 ◽

2021 ◽

Vol 13 (19) ◽

pp. 4971

Author(s):

Shion Wei Chai ◽

Suo-Hsien Wang ◽

Chih-Yuan Wang ◽

Yi-Chan Chen ◽

Ruey-Shyang Soong ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Meta Analysis ◽

Disease Free Survival ◽

Systemic Review ◽

Cochrane Library ◽

Free Survival ◽

Significant Difference ◽

Hospital Stays ◽

Disease Free

Background: Surgical treatment is the key to cure localized gastric cancer. There is no strong evidence that supports the value of omentectomy. Thus, a meta-analysis was conducted to compare the safety and efficiency of partial and total omentectomy in patients with gastric cancer. Methods: PubMed, Embase, and Cochrane Library databases were searched. All studies that compared total and partial omentectomy as treatments for gastric cancer were included. The primary outcomes were patients’ overall survival and disease-free survival, while the secondary outcomes were perioperative outcome and postoperative complications. Results: A total of nine studies were examined, wherein 1043 patients were included in the partial omentectomy group, and 1995 in the total omentectomy group. The partial omentectomy group was associated with better overall survival (hazard ratio: 0.80, 95% CI: 0.66 to 0.98, p = 0.04, I2 = 0%), shorter operative time, and lesser blood loss than the total omentectomy group. In addition, no statistically significant difference was observed in the number of dissected lymph nodes, length of hospital stays, complication rate, and disease-free survival. Conclusions: Our results show that, compared with total omentectomy in gastric cancer surgery, partial omentectomy had non-inferior oncological outcomes and comparable safety outcomes.

Download Full-text

Correlation between miR-200 Family Overexpression and Cancer Prognosis

Disease Markers ◽

10.1155/2018/6071826 ◽

2018 ◽

Vol 2018 ◽

pp. 1-16 ◽

Cited By ~ 2

Author(s):

Wen Liu ◽

Kaiping Zhang ◽

Pengfei Wei ◽

Yue Hu ◽

Yaqin Peng ◽

...

Keyword(s):

Meta Analysis ◽

Disease Free Survival ◽

Progression Free Survival ◽

Convincing Evidence ◽

Test Method ◽

Cancer Prognosis ◽

Cochrane Library ◽

Cancer Type ◽

China National Knowledge Infrastructure ◽

Free Survival

The correlation between miR-200 family overexpression and cancer prognosis remains controversial. Therefore, we conducted a systematic review and meta-analysis by searching PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), and China National Knowledge Infrastructure (CNKI) to identify eligible studies. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the correlations. Additionally, different subgroup analyses and publication bias test were performed. Eventually, we analyzed 23 articles that included five tumor types and 3038 patients. Consequently, high expression of miR-200 family in various tumors was associated with unfavorable overall survival (OS) in both univariate (HR=1.32, 95% CI: 1.14–1.54, P<0.001) and multivariate (HR=1.32, 95% CI: 1.16–1.49, P<0.001) analyses. Likewise, a similar result was found in different subgroups of the patient source, cancer type, test method, sample source, miR-200 component, and sample size. However, no association of miR-200 family was detected with recurrence- or relapse-free survival (RFS) (univariate: HR=1.02, 95% CI: 0.96–1.09, P=0.47; multivariate: HR=1.07, 95% CI: 1.00–1.14, P=0.07), progression-free survival (PFS) (univariate: HR=0.96, 95% CI: 0.54–1.70, P=0.88; multivariate: HR=1.17, 95% CI: 0.86–1.61, P=0.32), and disease-free survival (DFS) (univariate: HR=0.90, 95% CI: 0.74–1.09, P=0.29; multivariate: HR=0.98, 95% CI: 0.68–1.41, P=0.90). Our findings have provided convincing evidence that miR-200 family overexpression suggested poor prognosis of various cancer types, which efforts may raise the potential use of miR-200 family for cancer prognosis in clinical practice.

Download Full-text

Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis

British Journal of Cancer ◽

10.1038/bjc.1997.442 ◽

1997 ◽

Vol 76 (5) ◽

pp. 661-666 ◽

Cited By ~ 66

Author(s):

G Ferrandina ◽

G Scambia ◽

F Bardelli ◽

P Benedetti Panici ◽

S Mancuso ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Cathepsin D ◽

Meta Analysis ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Node Negative ◽

Node Negative Breast Cancer ◽

Disease Free

Download Full-text

Overexpression of lncRNA SNGH3 Predicts Unfavorable Prognosis and Clinical Outcomes in Human Cancers: Evidence from a Meta-Analysis

BioMed Research International ◽

10.1155/2020/7974034 ◽

2020 ◽

Vol 2020 ◽

pp. 1-13

Author(s):

Yaofei Jiang ◽

Lulu Le

Keyword(s):

Clinical Outcomes ◽

Histological Grade ◽

Meta Analysis ◽

Disease Free Survival ◽

The Cancer Genome Atlas ◽

Cochrane Library ◽

Cancer Type ◽

Free Survival ◽

Human Cancers ◽

Tcga Dataset

Long noncoding RNAs (lncRNAs) have been confirmed to play a crucial role in human disease, especially in tumor development and progression. Small nucleolar RNA host gene (SNHG3), a newly identified lncRNA, has been found dysregulated in various cancers. Nevertheless, the results remain controversial. Thus, we aim to analyze the comprehensive data to elaborate the association between SNHG3 expression and clinical outcomes in multiple cancers. We searched PubMed, Web of Science, Cochrane Library, Embase, and MEDLINE database to identify eligible articles. STATA software was applied to calculate the hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (95% CI) for survival outcomes and clinical parameters, respectively. Besides, the data from The Cancer Genome Atlas (TCGA) dataset was extracted to verify the results in our meta-analysis. There were thirteen studies totaling 919 cancer patients involved in this meta-analysis. The results demonstrated that high SNHG3 expression was significantly associated with poor overall survival (OS) (HR=2.53, 95% CI: 1.94-3.31) in cancers, disease-free survival (DFS) (HR=3.89, 95% CI: 1.34-11.3), and recurrence-free survival (RFS) (HR=2.42, 95% CI: 1.14-5.15) in hepatocellular carcinoma. Analysis stratified by analysis method, sample size, follow-up time, and cancer type further verified the prognostic value of SNHG3. Additionally, patients with high SNHG3 expression tended to have more advanced clinical stage, higher histological grade, earlier distant metastasis, and earlier lymph node metastasis. Excavation of TCGA dataset valuated that SNHG3 was upregulated in various cancers and predicted worse OS and DFS. Overexpressed SNHG3 was strongly associated with poor survival and clinical outcomes in human cancers and therefore can serve as a promising biomarker for predicting patients’ prognosis.

Download Full-text

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis

Journal of International Medical Research ◽

10.1177/0300060520962675 ◽

2020 ◽

Vol 48 (10) ◽

pp. 030006052096267

Author(s):

Qian Zhang ◽

Kexiang Zhou ◽

Wei Liang ◽

Wei Xiong

Keyword(s):

Hepatocellular Carcinoma ◽

Meta Analysis ◽

Disease Free Survival ◽

Tumor Stage ◽

Alpha Fetoprotein ◽

Biomedical Literature ◽

Free Survival ◽

Programmed Cell Death 1 ◽

Clinicopathological Significance ◽

Disease Free

Objective We performed a meta-analysis to evaluate the prognostic and clinicopathological significance of programmed cell death-1 (PD-1) expression in patients with hepatocellular carcinoma (HCC). Methods We searched the Wanfang, Chinese Biomedical Literature, CNKI, PubMed, Embase, and Web of Science databases for relevant articles from inception to 1 July 2020. Statistical analysis was performed using RevMan 5.3 (Cochrane, London, UK) and Stata 14.0 software (StataCorp LP, College Station, TX, USA). Results Eight studies involving 732 patients with HCC were included. Higher expression of PD-1 predicted longer disease-free survival [hazard ratio (HR) 0.53, 95% confidence interval (CI): 0.38–0.72]. No significant correlation was observed between PD-1 expression and overall survival (HR 0.89, 95% CI: 0.58–1.35). PD-1 expression was correlated with age [odds ratio (OR) 0.66, 95% CI: 0.46–0.94] and alpha-fetoprotein level (OR 2.27, 95% CI: 1.45–3.55); no correlation was observed with sex, tumor size, tumor metastasis, hepatitis B virus history, tumor stage, or tumor multiplicity. Sensitivity analysis demonstrated no excessive effect on stability of the pooled results. No significant publication bias was found among the identified studies. Conclusion PD-1 overexpression predicted better disease-free survival in patients with HCC. Moreover, PD-1 expression was associated with age and alpha-fetoprotein level.

Download Full-text